

# Identify Research Needs and Support Product-Specific Guidance (PSG) Development for Complex Products

Advancing Generic Development / Translating Science to Approval

Xiaoming Xu, Ph.D.

Director, Division of Product Quality Research  
Office of Testing and Research, Office of Pharmaceutical Quality  
CDER | U.S. FDA

September 14, 2023



# Outline



- Generic Drug User Fee Amendments (GDUFA) Regulatory Science Program
- Product-Specific Guidance (PSG) Program
- Approach to Proactively Identify Research Needs for Complex Products

# GDUFA Regulatory Science Program



The Generic Drug User Fee Amendments (GDUFA), first enacted in 2012, enables FDA to assess industry user fees to bring greater predictability and timeliness to the review of generic drug applications. To advance generic drug regulatory science and decision-making, GDUFA provides resources that allow FDA to fund research.

- Since FY2013, FDA has awarded over 200 research contracts and grants as well as conducted numerous projects led by FDA staff.
- GDUFA research provides new tools for FDA and industry to evaluate generic drug equivalence. This enables more efficient development and review of generic drugs, including the development of PSG recommendations.
- Results from GDUFA research are presented at scientific and public meetings as well as published in peer-reviewed scientific journals.

# Product-Specific Guidance (PSG)



- A key outcome of GDUFA research is the development of PSGs.
- Started in 2007, PSGs outline FDA's current product-specific thinking on the type of studies and information to support the development and approval of a safe, effective, and high-quality generic drug product.
- PSGs are drug-specific recommendations for demonstrating *therapeutic equivalence* of a generic product to the Reference Listed Drug (RLD) product
  - ❑ PSGs are posted on a quarterly basis
  - ❑ As of August 2023, there are over 2100 posted PSGs
- FDA develops and posts PSGs to:
  - ❑ Enhance transparent expectations and conversation between the Agency and the generic industry
  - ❑ Reduce industry inquiries by providing a general framework for generic product development
  - ❑ Improves the quality of submitted ANDAs

# PSG (cont.)



Contains Nonbinding Recommendations

## Draft Guidance on Cyclosporine

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient:	Cyclosporine
Dosage Form; Route:	Emulsion; ophthalmic
Strength:	0.05%
Recommended Study:	Two options: in vitro or in vivo study

### I. In vitro option:

To qualify for the in vitro option for this drug product all of the following criteria should be met:

- The test and reference listed drug (RLD) formulations are qualitatively (Q1)<sup>1</sup> and quantitatively (Q2)<sup>2</sup> the same<sup>3</sup>.
- Acceptable comparative physicochemical characterizations of the test and RLD formulations. The comparative study should be performed on at least three exhibit batches of both test and RLD products<sup>4</sup>.

**Parameters to measure:** Globule size distribution, viscosity profile as a function of applied shear, pH, zeta potential, osmolality and surface tension. Sponsors should use a dynamic light scattering method (or PCS, QELS) to measure the globule size of the test

**Parameters to measure:** Globule size distribution, viscosity profile as a function of applied shear, pH, zeta potential, osmolality and surface tension. Sponsors should use a dynamic light scattering method (or PCS, QELS) to measure the globule size of the test and RLD formulations, and provide comparable size distribution profiles (intensity-weighted histograms) upon serial dilutions. Information on the instrument, analysis mode (if applicable), dilution medium, and level of dilution used for globule size measurement should be provided.

- To support a bioequivalence determination, PSGs commonly recommend a type of study or property of the drug product to measure.
- GDUFA research can inform FDA and industry regarding new tools, including potential development and assessment considerations for a particular analytical approach for a specific product or class of products.
- The properties of complex products are often important, interrelated, and not straightforward to measure or compare.
  - *Research provides the insight to develop a recommended BE approach and a starting point for product development*

# PSG for Complex Product and GDUFA III

GDUFA III Commitment Letter: <https://www.fda.gov/media/153631/download>

## Section III.C Product-Specific Guidance


1. FDA will continue to issue PSG identifying the methodology for generating evidence needed to support ANDA approval.
2. FDA will issue PSGs consistent with the following **goals**:
  - a. **For Complex Products approved in new drug applications (NDAs) on or after October 1, 2022, a PSG will be issued for 50 percent of such NDA products within 2 years after the date of approval, and for 75 percent of such NDA products within 3 years after the date of approval.**
  - b. FDA will continue to develop PSGs for Complex Products approved prior to October 1, 2022, for which no PSG has been published.
  - c. For non-complex drug products approved in NDAs on or after October 1, 2022, that contain a new chemical entity (NCE) (as described in section 505(j)(5)(F)(ii) of the FD&C Act), a PSG will be issued within 2 years after the date of approval for 90 percent of such products.

**To meet this new goal, we will need to identify and address any potential complexities and research needs for PSG development soon after NDA approval.**

# The Challenges



- Depending on complexity of a newly approved New Drug Application (NDA), the timeline to develop the PSG may need/benefit from:
  - Knowledge transfer from the NDA review team and other SMEs
  - Additional information from research



# Challenges and Opportunities (cont.)




Challenges	Opportunities
Complexities vary (e.g., formulation, dosage form, route of delivery, complex API)	Collaboration
Scientific knowledge gap (e.g., new material, technology, complex process, critical quality attributes)	Research and innovation
Need for reliable/new analytical methods	Research and innovation
Time constraints (especially if involving additional research to generate evidence)	Early engagement
Life-cycle of the product (NDA to ANDA, supplement)	Communication and collaboration



# Cyclosporine Ophthalmic Emulsions: A Case Study



RLD: Restasis (cyclosporine ophthalmic emulsions) 0.05%




Research generated crucial supporting data which allowed for assessment of product-specific quality attributes, best measurement practices and assessment criteria to support equivalence. However, it took nearly 10 years from approval to develop scientific recommendations and another 9 years to translate to approval.

- Z. Rahman et al. *Mol Pharm* (2014), 11, 3.
- H. Qu, et al. *Int J Pharm* (2018), 538, p.215-222
- P. Petrochenko, et al. *Int J Pharm* (2019), 550, p229-239
- Y. Dong et al. *J Pharm Sci* (2019) 108, 2002-2011

- Y. Dong et al. *J Control Release* (2019), 313, 96-105
- Y. Dong et al. *J Control Release* (2020), 327, 360-370
- D. Patel et al. *J Control Release* (2021), 333, 65-75.
- R. Bellantone, et al. *Int J Pharm* (2022), 121521.

- An internal program to identify and direct research to support PSG development of complex generics
- 10 complex areas
- SMEs across 9 CDER offices
- Over the last two years, conducted 59 SME triage team meetings of newly approved NDAs, with 8 identified research projects




# SME Triage Team Program:



- Established a cross-office program (SME Triage Team, STT), specifically to support PSG development
- STT program clarified relevant CDER offices of roles and responsibilities in the development process of complex product PSGs.
- STT program successfully connected research and review assessment with PSG development, achieving early identification of knowledge gaps and timely addressing technical challenges.
- Identify product based on complexity area, e.g., ophthalmic, inhalation, dermatological.
- Each complex area has its own SME team, with membership comprises of experts from research, review, and policy.
- SME team make key decisions like: Identify area of complexity; Determine if the complexity needs new research; Decide the research objectives.
- STT program enabled cross-disciplinary collaboration for effective knowledge management to maximize efficient use of Center resources.
- STT program started as a pilot in 2021 and became fully operational in Oct 2022.

# Timeline to Support Complex Product PSG



VERKAZIA, cyclosporine emulsion  
(NDA 214965)

Approval: 6/23/2021

PSG Published: 8/2/2022

14 months to publish PSG



DEXTENZA (dexamethasone  
ophthalmic insert, NDA 208742)  
Approval: 11/30/2018

Research is ongoing to address knowledge gaps in  
material characterization and Q3 attributes\*.

# Today (cont.): PSG Forecast List



The screenshot shows the FDA's website for upcoming product-specific guidances. The page has a blue header with the FDA logo and navigation links. The main heading is 'Upcoming Product-Specific Guidances for Generic Drug Product Development'. Below this, there is an 'Introduction' section and a 'How often does FDA publish new and revised PSGs?' section. The 'Introduction' section states that the page provides information related to upcoming new and revised product-specific guidances (PSGs) to support the development and approval of safe and effective generic drug products. It mentions a commitment under the Generic Drug User Fee Amendments of 2022 (GDUFA III) to publish PSGs for both complex and non-complex products planned for the next 12 months. The 'How often does FDA publish new and revised PSGs?' section explains that the FDA issues new and revised PSGs on a quarterly and as needed basis, describing the agency's current thinking and expectations on how to develop generic drug products to specific reference listed drugs and intended to assist the generic pharmaceutical industry with identifying the most appropriate methodology and evidence needed to support a specific generic drug's approval.

**Upcoming Product-Specific Guidances for Generic Drug Product Development**

**Introduction**

This web page provides information related to upcoming new and revised product-specific guidances (PSGs) to support the development and approval of safe and effective generic drug products, including the projected date of PSG publication, as a commitment under the [Generic Drug User Fee Amendments of 2022 \(GDUFA III\)](#). Upcoming PSGs for both complex and non-complex products that are planned to be published in the next 12 months are listed (these may be subject to change).

**How often does FDA publish new and revised PSGs?**

To support generic drug development and generic drug approval, FDA issues new and revised PSGs on a quarterly and as needed basis. These PSGs, including PSGs for both complex and non-complex generic drug products, when finalized, describe the agency's current thinking and expectations on how to develop generic drug products to specific reference listed drugs and are intended to assist the generic pharmaceutical industry with identifying the most appropriate methodology and evidence needed to support a specific generic drug's approval. The [published PSGs](#) are announced in the Federal Register and made available to the public on FDA's website.

Planned New PSGs for Complex and Non-Complex Generic Drug Products					
Updated May 18, 2023					
Active ingredient(s)	Route of Administration	Dosage Form	RLD or RS Application Number	Product Complexity	Planned Publication
Abacavir	Oral	Tablet	212071	Non-Complex	06/2023
Adagrasib	Oral	Tablet	216340	Non-Complex	05/2024
Amikacin Sulfate	Inhalation	Suspension, Liposomal	207356	Complex	05/2024
Amoxicillin, Clarithromycin, Voriconazole Fumarate	Oral	Capsule, Tablet, Tablet	215152	Non-Complex	11/2023
Amoxicillin, Vortioxetine Fumarate	Oral	Capsule, Tablet	215153	Non-Complex	11/2023
Aprepitant	Intravenous	Emulsion	216457	Complex	06/2023
Aripiprazole	Oral	Tablet	207202	Complex	Within the next 12 months
Aciniclovir Hydrochloride	Oral	Tablet	215356	Non-Complex	06/2023
Allopurinol	Oral	Tablet	215206	Non-Complex	06/2023
Alverdin Calcium	Oral	Suspension	213363	Non-Complex	05/2024
Atropine Sulfate	Ophthalmic	Solution/Drops	215581	Non-Complex	05/2023
Avacopan	Oral	Capsule	214487	Non-Complex	06/2023
Azathioprine	Oral	Tablet	214120	Non-Complex	11/2023
Baclofen	Oral	Granules	215422	Non-Complex	02/2024
Bexagliflozin	Oral	Tablet	214375	Non-Complex	05/2024

# Summary



- FDA's product-specific guidance program provides FDA's current thinking on the type of studies and information to support the development and approval of safe, effective, and high-quality generic drug products.
- GDUFA research offers opportunity for targeted generation of evidence and knowledge in areas of high complexity and challenge.
- Lifecycle approach towards knowledge generation and information sharing is critical to the timely development of PSG.

# Acknowledgment

- Darby Kozak
- Rangeeta Kumari
- OGD PSG Team
- OPQ
- OGD



# Challenge Question #1



- GDUFA research can facilitate:
  - A. PSG development
  - B. ANDA assessment
  - C. Generic product development
  - D. All of the above

# Challenge Question #1



- GDUFA research can facilitate:
  - A. PSG development
  - B. ANDA assessment
  - C. Generic product development
  - D. All of the above



**U.S. FOOD & DRUG**  
ADMINISTRATION